BOULDER, Colo.–(BUSINESS WIRE)–VitriVax, Inc., an innovative vaccine development and formulation technology company, today announced the close of an oversubscribed $87 million Series C financing. The investment was co-led by F-Prime, NEA, RA Capital Management, and Sanofi Ventures with participation from Eli Lilly and Company as well as other existing investors. The funding will be used to advance VitriVax’s lead program, a Lyme disease vaccine candidate with a novel mechanism of action, into

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.